NCT02104284

Brief Summary

Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity and specificity for asthma diagnosis. Response-dose-ratio was also compared.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
104

participants targeted

Target at P50-P75 for not_applicable asthma

Timeline
Completed

Started Jul 2011

Typical duration for not_applicable asthma

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 21, 2014

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 4, 2014

Completed
Last Updated

April 4, 2014

Status Verified

April 1, 2014

Enrollment Period

2.4 years

First QC Date

March 21, 2014

Last Update Submit

April 2, 2014

Conditions

Keywords

Bronchial provocation testMannitolMethacholineBronchial hyperreactivitySensitivity and specificity

Outcome Measures

Primary Outcomes (1)

  • sensitivity comparison of the mannitol challenge test and methacholine challenge test

    The diagnostic properties of the mannitol challenge test and methacholine challenge test (sensitivity, specificity, positive predictive value, and negative predictive value) were calculated against the physician's diagnosis of asthma. methacholine challenge test: positive at PC20 \< 16 mg/mL mannitoln test: positive if FEV1 fell by more than 15% until the last dose (until a cumulative dose of 635 mg) gold standard: physician's diagnosis of asthma sensitivity: true positive / true positive+false negative

    60 minutes

Secondary Outcomes (3)

  • specificity comparison of the mannitol challenge test and methacholine challenge test

    60 minutes

  • positive predictive value comparison of the mannitol challenge test and methacholine challenge test

    60 minutes

  • negative predictive value comparison of the mannitol challenge test and methacholine challenge test

    60 minutes

Study Arms (4)

Normal controls, methacholine positive

OTHER

methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in normal controls

Procedure: methacholine and mannitol bronchial challenge tests

Normal controls, mannitol

OTHER

methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in normal controls.

Procedure: methacholine and mannitol bronchial challenge tests

Asthma, Methacholine

ACTIVE COMPARATOR

methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in asthmatics

Procedure: methacholine and mannitol bronchial challenge tests

Asthma, Mannitol

ACTIVE COMPARATOR

methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in asthmatics

Procedure: methacholine and mannitol bronchial challenge tests

Interventions

Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests. Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.

Asthma, MannitolAsthma, MethacholineNormal controls, mannitolNormal controls, methacholine positive

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • History of recent respiratory infection (within the last 4 weeks)
  • History of a recent surgery
  • History of heart disease that could impose risks during bronchial challenges
  • History of uncontrolled hypertension
  • Current smokers or ex-smokers with more than 10 pack-years
  • History of known pulmonary diseases with the exception of asthma
  • Pregnancy or lactation
  • Severe obesity (body mass index \[BMI\] of \>35 kg/m2)
  • History of any health condition considered inappropriate for participation in this study
  • Pre-bronchodilator predictive value of forced expiratory volume in 1 second (FEV1) of \<70%

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Kim MH, Song WJ, Kim TW, Jin HJ, Sin YS, Ye YM, Kim SH, Park HW, Lee BJ, Park HS, Yoon HJ, Choi DC, Min KU, Cho SH. Diagnostic properties of the methacholine and mannitol bronchial challenge tests: a comparison study. Respirology. 2014 Aug;19(6):852-6. doi: 10.1111/resp.12334. Epub 2014 Jun 26.

MeSH Terms

Conditions

AsthmaBronchial HyperreactivityHypersensitivity

Interventions

Methacholine Chloride

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateImmune System Diseases

Intervention Hierarchy (Ancestors)

Methacholine CompoundsTrimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium Compounds

Study Officials

  • Sang-Heon Cho, M.D.,Ph.D.

    Seoul National University College of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 21, 2014

First Posted

April 4, 2014

Study Start

July 1, 2011

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

April 4, 2014

Record last verified: 2014-04